Loading
Peter Bartenstein is a nuclear medicine head whose department is a leading European PSMA theranostics centre.
Peter Bartenstein is Director of the Department of Nuclear Medicine at LMU Klinikum München. His specialisms are nuclear medicine, PSMA theranostics and neuro-imaging. His department is a leading European centre for PSMA PET and lutetium-177 PSMA radioligand therapy, and it co-developed 177Lu-PSMA-I&T. His papers include a dosimetry study of 177Lu-DKFZ-PSMA-617 as a new radiopharmaceutical for metastatic prostate cancer, the first clinical results of 18F-SiFAlin-TATE PET for imaging neuroendocrine tumours, and a European Urology study showing that 68Ga-PSMA PET/CT accurately stages lymph node regions before dissection in prostate cancer. His publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer | European Journal of Nuclear Medicine and Molecular Imaging | 2015 |
| Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors | European Journal of Nuclear Medicine and Molecular Imaging | 2019 |
| 68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer | European Urology | 2016 |
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
Shares 177Lu-PSMA-I&T, Radioligand therapy (beta emitters), Prostate cancer.
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
Shares PSMA, Radioligand therapy (beta emitters), Prostate cancer.